Jyong Biotech Ltd. (MENS)
NASDAQ: MENS · Real-Time Price · USD
2.150
-0.010 (-0.46%)
Jun 3, 2026, 1:53 PM EDT - Market open
Jyong Biotech Employees
Jyong Biotech had 27 employees as of December 31, 2025. The number of employees decreased by 4 or -12.90% compared to the previous year.
Employees
27
Change
-4
Growth
-12.90%
Revenue / Employee
n/a
Profits / Employee
-$173,000
Market Cap
159.60M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 27 | - | - |
| Jun 30, 2024 | 31 | - | - |
| Dec 31, 2023 | 31 | -1 | -3.13% |
| Dec 31, 2022 | 32 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| ProQR Therapeutics | 187 |
| Molecular Partners AG | 134 |
| Tenaya Therapeutics | 70 |
| Precision BioSciences | 66 |
| Acumen Pharmaceuticals | 61 |
| Korro Bio | 49 |
| OnKure Therapeutics | 45 |
MENS News
- 5 days ago - Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview - GlobeNewsWire
- 19 days ago - Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025 - GlobeNewsWire
- 19 days ago - Jyong Biotech Annual report: Q4 2025 - Filings
- 5 weeks ago - Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio - GlobeNewsWire
- 2 months ago - Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2 - GlobeNewsWire
- 3 months ago - Jyong issues strategic corporate update, completes Phase II trial for MCS-8 - TheFly
- 3 months ago - Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia - GlobeNewsWire
- 4 months ago - Jyong Biotech subsidiary announces phase II data for MCS-8 - TheFly